20-HETE and F2-isoprostanes in the metabolic syndrome: the effect of weight reduction

I-Jung Tsai, Kevin Croft, Trevor Mori, J.R. Falck, Lawrence Beilin, Ian Puddey, Anne Barden

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

20-Hydroxyeicosatetraenoic acid (20-HETE) is a cytochrome P450 metabolite of arachidonic acid that regulates vascular function and sodium homeostasis. Studies showing an association between 20-HETE excretion, raised BMI, and oxidative stress suggest that 20-HETE may be important in the development of cardiovascular disease in the metabolic syndrome (MetS). We investigated whether 20-HETE and F2-isoprostanes (markers of oxidative stress) were altered in the MetS before and after weight reduction. A case-controlled comparison of 30 participants with the MetS and matched controls showed that plasma and urinary 20-HETE and F2-isoprostanes were significantly elevated in the MetS group. There was a significant gender × group interaction such that women with the MetS had higher urinary 20-HETE and F2-isoprostanes compared to controls (p <0.0001). In a randomized controlled trial, 42 participants with the MetS were assigned to 16 weeks of weight maintenance or a 12-week weight-loss program followed by 4 weeks weight stabilization. Relative to the weight-maintenance group, a 4-kg loss in weight resulted in a 2-mm Hg fall in blood pressure (BP) but did not alter urinary or plasma 20-HETE or F2-isoprostanes. 20-HETE and oxidative stress may be important mediators of cardiovascular disease risk in the MetS. Although a 4% reduction in body weight reduced BP, there were no changes in plasma or urinary 20-HETE or F2-isoprostanes.
Original languageEnglish
Pages (from-to)263-270
JournalFree Radical Biology and Medicine
Volume46
Issue number2
DOIs
Publication statusPublished - 2009

Fingerprint

F2-Isoprostanes
Weight Loss
Oxidative stress
Oxidative Stress
Blood pressure
Plasmas
Weights and Measures
Cardiovascular Diseases
Maintenance
Blood Pressure
Weight Reduction Programs
20-hydroxy-5,8,11,14-eicosatetraenoic acid
Metabolites
Arachidonic Acid
Cytochrome P-450 Enzyme System
Blood Vessels
Homeostasis
Randomized Controlled Trials
Stabilization
Sodium

Cite this

@article{8db24805a0e349918c3bfbb76459091b,
title = "20-HETE and F2-isoprostanes in the metabolic syndrome: the effect of weight reduction",
abstract = "20-Hydroxyeicosatetraenoic acid (20-HETE) is a cytochrome P450 metabolite of arachidonic acid that regulates vascular function and sodium homeostasis. Studies showing an association between 20-HETE excretion, raised BMI, and oxidative stress suggest that 20-HETE may be important in the development of cardiovascular disease in the metabolic syndrome (MetS). We investigated whether 20-HETE and F2-isoprostanes (markers of oxidative stress) were altered in the MetS before and after weight reduction. A case-controlled comparison of 30 participants with the MetS and matched controls showed that plasma and urinary 20-HETE and F2-isoprostanes were significantly elevated in the MetS group. There was a significant gender × group interaction such that women with the MetS had higher urinary 20-HETE and F2-isoprostanes compared to controls (p <0.0001). In a randomized controlled trial, 42 participants with the MetS were assigned to 16 weeks of weight maintenance or a 12-week weight-loss program followed by 4 weeks weight stabilization. Relative to the weight-maintenance group, a 4-kg loss in weight resulted in a 2-mm Hg fall in blood pressure (BP) but did not alter urinary or plasma 20-HETE or F2-isoprostanes. 20-HETE and oxidative stress may be important mediators of cardiovascular disease risk in the MetS. Although a 4{\%} reduction in body weight reduced BP, there were no changes in plasma or urinary 20-HETE or F2-isoprostanes.",
author = "I-Jung Tsai and Kevin Croft and Trevor Mori and J.R. Falck and Lawrence Beilin and Ian Puddey and Anne Barden",
year = "2009",
doi = "10.1016/j.freeradbiomed.2008.10.028",
language = "English",
volume = "46",
pages = "263--270",
journal = "Free Radical Biology & Medicine",
issn = "0891-5849",
publisher = "Academic Press",
number = "2",

}

20-HETE and F2-isoprostanes in the metabolic syndrome: the effect of weight reduction. / Tsai, I-Jung; Croft, Kevin; Mori, Trevor; Falck, J.R.; Beilin, Lawrence; Puddey, Ian; Barden, Anne.

In: Free Radical Biology and Medicine, Vol. 46, No. 2, 2009, p. 263-270.

Research output: Contribution to journalArticle

TY - JOUR

T1 - 20-HETE and F2-isoprostanes in the metabolic syndrome: the effect of weight reduction

AU - Tsai, I-Jung

AU - Croft, Kevin

AU - Mori, Trevor

AU - Falck, J.R.

AU - Beilin, Lawrence

AU - Puddey, Ian

AU - Barden, Anne

PY - 2009

Y1 - 2009

N2 - 20-Hydroxyeicosatetraenoic acid (20-HETE) is a cytochrome P450 metabolite of arachidonic acid that regulates vascular function and sodium homeostasis. Studies showing an association between 20-HETE excretion, raised BMI, and oxidative stress suggest that 20-HETE may be important in the development of cardiovascular disease in the metabolic syndrome (MetS). We investigated whether 20-HETE and F2-isoprostanes (markers of oxidative stress) were altered in the MetS before and after weight reduction. A case-controlled comparison of 30 participants with the MetS and matched controls showed that plasma and urinary 20-HETE and F2-isoprostanes were significantly elevated in the MetS group. There was a significant gender × group interaction such that women with the MetS had higher urinary 20-HETE and F2-isoprostanes compared to controls (p <0.0001). In a randomized controlled trial, 42 participants with the MetS were assigned to 16 weeks of weight maintenance or a 12-week weight-loss program followed by 4 weeks weight stabilization. Relative to the weight-maintenance group, a 4-kg loss in weight resulted in a 2-mm Hg fall in blood pressure (BP) but did not alter urinary or plasma 20-HETE or F2-isoprostanes. 20-HETE and oxidative stress may be important mediators of cardiovascular disease risk in the MetS. Although a 4% reduction in body weight reduced BP, there were no changes in plasma or urinary 20-HETE or F2-isoprostanes.

AB - 20-Hydroxyeicosatetraenoic acid (20-HETE) is a cytochrome P450 metabolite of arachidonic acid that regulates vascular function and sodium homeostasis. Studies showing an association between 20-HETE excretion, raised BMI, and oxidative stress suggest that 20-HETE may be important in the development of cardiovascular disease in the metabolic syndrome (MetS). We investigated whether 20-HETE and F2-isoprostanes (markers of oxidative stress) were altered in the MetS before and after weight reduction. A case-controlled comparison of 30 participants with the MetS and matched controls showed that plasma and urinary 20-HETE and F2-isoprostanes were significantly elevated in the MetS group. There was a significant gender × group interaction such that women with the MetS had higher urinary 20-HETE and F2-isoprostanes compared to controls (p <0.0001). In a randomized controlled trial, 42 participants with the MetS were assigned to 16 weeks of weight maintenance or a 12-week weight-loss program followed by 4 weeks weight stabilization. Relative to the weight-maintenance group, a 4-kg loss in weight resulted in a 2-mm Hg fall in blood pressure (BP) but did not alter urinary or plasma 20-HETE or F2-isoprostanes. 20-HETE and oxidative stress may be important mediators of cardiovascular disease risk in the MetS. Although a 4% reduction in body weight reduced BP, there were no changes in plasma or urinary 20-HETE or F2-isoprostanes.

U2 - 10.1016/j.freeradbiomed.2008.10.028

DO - 10.1016/j.freeradbiomed.2008.10.028

M3 - Article

VL - 46

SP - 263

EP - 270

JO - Free Radical Biology & Medicine

JF - Free Radical Biology & Medicine

SN - 0891-5849

IS - 2

ER -